Search
for
Sort by
Research 781–810 of 1000+
- A case of aromatase inhibitor‐induced alopecia successfully treated with low‐dose oral minoxidil
- Harmless Herbs? A Review of the Recent Literature
- Drug Repurposing for Rare Diseases
- Epidemiology, Diagnosis, and Treatment of Atopic Dermatitis in the Developing Countries of Asia, Africa, Latin America, and the Middle East: A Review
- How drug repurposing can advance drug discovery: challenges and opportunities
- Hair loss
- Flutamide-Loaded Zein Nanocapsule Hydrogel, a Promising Dermal Delivery System for Pilosebaceous Unit Disorders
- Successive Release of Tissue Inhibitors of Metalloproteinase-1 Through Graphene Oxide-Based Delivery System Can Promote Skin Regeneration
- Survey on adverse events associated with drug therapy for breast cancer patients
- Side Effects Related to 5 α-Reductase Inhibitor Treatment of Hair Loss in Women: A Review.
- Dermatologic Conditions of the Early Post-Transplant Period in Hematopoietic Stem Cell Transplant Recipients
- Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis during Treatment with Tofacitinib: A Case Report
- Patterns of psychotropic medication prescribing and potential drug-hormone interactions among transgender and gender-diverse adults within 2 years of hormone therapy
- Drug-Induced Hair Loss: Analysis of the Food and Drug Administration’s Adverse Events Reporting System Database
- Cutaneous lupus erythematosus. Diagnostic and therapeutic recommendations of the Polish Dermatological Society
- Drug-induced Telogen Effluvium in a Pediatric Patient due to Error of Transcription.
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Hair Re-Pigmentation After Nilotinib
- Calcium channel inhibitor and extracellular calcium improve aminoglycoside-induced hair cell loss in zebrafish
- 397 Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials
- A randomized, blinded, three-arm, multicenter trial comparing the efficacy and safety of fluconazole given once daily for 3 or 6 weeks with griseofulvin given once daily for 6 weeks in pediatric patients with tinea capitis
- Alopecia areata in the United States: Outpatient utilization and common prescribing patterns
- Application of Scaffold-Based Drug Delivery in Oral Cancer Treatment: A Novel Approach
- Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- 5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder
- Microneedles as transdermal drug delivery system for enhancing skin disease treatment
- Identification of drug-specific public TCR driving severe cutaneous adverse reactions
- Changes in Expression and Function of Extrasynaptic GABA<sub>A</sub>Receptors in the Rat Hippocampus during Pregnancy and after Delivery
- The Effect of 5α-Reductase Inhibition With Dutasteride and Finasteride on Bone Mineral Density, Serum Lipoproteins, Hemoglobin, Prostate Specific Antigen and Sexual Function in Healthy Young Men